You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

152 search results for: type 2 inflammation

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview (Copy)
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview (Copy)

Dermatology
Watch ADVENT now: Dermatologist Mark Koh describes the Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children.
View more
UCARE <b>2</b>0<b>2</b>3: CSU – The Brazil Perspective
expert video

UCARE 2023: CSU – The Brazil Perspective

Dermatology
Dr. Ensina guides discussions on the perspective of CSU management in Brazil.
View more
UCARE <b>2</b>0<b>2</b>3: Non-Histaminergic Neuronal Sensitization in CSU
expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

Dermatology
Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.
View more
UCARE <b>2</b>0<b>2</b>3: Emerging Clinical Trial Data in CSU
expert video

UCARE 2023: Emerging Clinical Trial Data in CSU

Dermatology
Dr. Maurer explores current clinical data from leading emerging therapies in CSU.
View more
UCARE <b>2</b>0<b>2</b>3: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab
expert video

UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

Dermatology
Dr. Maurer summarises the implications of different modes of action of dupilumab, remibrutinib and barzolvolimab.
View more
Skin Dysbiosis in AD
expert video

Skin Dysbiosis in AD

Dermatology
Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Early Intervention in AD: Latest Clinical and Real-world Data
expert video

Early Intervention in AD: Latest Clinical and Real-world Data

Dermatology
Highlights from ESPD 2023 ADVENT: Reviewing the current treatment landscape and the potential for early intervention in pediatric atopic dermatitis.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region